Optimum Investment Advisors Gilead Sciences, Inc. Transaction History

Optimum Investment Advisors

$216 Million
Q1 2024

A detailed history of Optimum Investment Advisors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Optimum Investment Advisors holds 14,569 shares of GILD stock, worth $970,149. This represents 0.49% of its overall portfolio holdings.

Number of Shares

14,569

Previous 14,603 0.23%

Holding current value

$970,149

Previous $1.18 Million 9.73%

% of portfolio

0.49%

Previous 0.6%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$71.58 - $87.29 $2,433 - $2,967	-34 Reduced 0.23%	14,569 $1.07 Million
Q4 2023 Jan 08, 2024	SELL	$73.27 - $83.09 $150,936 - $171,165	-2,060 Reduced 12.36%	14,603 $1.18 Million
Q3 2023 Oct 13, 2023	SELL	$73.94 - $80.67 $26,026 - $28,395	-352 Reduced 2.07%	16,663 $1.25 Million
Q2 2023 Aug 03, 2023	SELL	$76.01 - $86.7 $20,826 - $23,755	-274 Reduced 1.58%	17,015 $1.31 Million
Q1 2023 May 03, 2023	SELL	$77.31 - $88.08 $67,568 - $76,981	-874 Reduced 4.81%	17,289 $1.43 Million

Q4 2022 Jan 05, 2023	SELL	$62.32 - $89.47 $268,225 - $385,078	-4,304 Reduced 19.16%	18,163 $0
Q3 2022 Oct 24, 2022	SELL	$59.54 - $68.01 $140,752 - $160,775	-2,364 Reduced 9.52%	22,467 $1.39 Million
Q2 2022 Jul 12, 2022	SELL	$57.72 - $65.01 $1,731 - $1,950	-30 Reduced 0.12%	24,831 $1.54 Million
Q1 2022 Apr 08, 2022	SELL	$57.92 - $72.58 $5,792 - $7,258	-100 Reduced 0.4%	24,861 $1.48 Million
Q4 2021 Mar 17, 2022	SELL	$64.88 - $73.64 $42,626 - $48,381	-657 Reduced 2.56%	24,961 $1.81 Million
Q3 2021 Oct 22, 2021	SELL	$67.69 - $73.03 $317,398 - $342,437	-4,689 Reduced 15.47%	25,618 $1.79 Million
Q3 2021 Oct 12, 2021	SELL	$67.69 - $73.03 $10,491 - $11,319	-155 Reduced 0.51%	30,307 $2.09 Million
Q2 2021 Aug 02, 2021	SELL	$63.47 - $69.35 $38,082 - $41,610	-600 Reduced 1.93%	30,462 $2.1 Million
Q1 2021 Apr 15, 2021	SELL	$60.0 - $68.46 $62,400 - $71,198	-1,040 Reduced 3.24%	31,062 $2.01 Million
Q4 2020 Jan 21, 2021	SELL	$56.65 - $64.55 $146,950 - $167,442	-2,594 Reduced 7.48%	32,102 $1.87 Million
Q3 2020 Oct 06, 2020	SELL	$62.1 - $78.08 $112,401 - $141,324	-1,810 Reduced 4.96%	34,696 $2.19 Million
Q2 2020 Jul 16, 2020	BUY	$72.34 - $84.0 $31,829 - $36,960	440 Added 1.22%	36,506 $2.81 Million
Q1 2020 Apr 21, 2020	SELL	$62.63 - $80.22 $243,943 - $312,456	-3,895 Reduced 9.75%	36,066 $2.7 Million
Q4 2019 Jan 22, 2020	SELL	$61.62 - $67.78 $154,050 - $169,450	-2,500 Reduced 5.89%	39,961 $2.6 Million
Q3 2019 Oct 17, 2019	SELL	$62.51 - $69.0 $245,351 - $270,825	-3,925 Reduced 8.46%	42,461 $2.69 Million
Q2 2019 Jul 29, 2019	SELL	$61.87 - $69.38 $255,832 - $286,886	-4,135 Reduced 8.18%	46,386 $3.13 Million
Q1 2019 May 03, 2019	SELL	$62.53 - $70.05 $234,612 - $262,827	-3,752 Reduced 6.91%	50,521 $3.28 Million
Q4 2018 Feb 04, 2019	SELL	$60.54 - $79.0 $64,777 - $84,530	-1,070 Reduced 1.93%	54,273 $3.4 Million
Q3 2018 Oct 05, 2018	SELL	$71.28 - $78.92 $405,298 - $448,739	-5,686 Reduced 9.32%	55,343 $4.27 Million
Q2 2018 Oct 05, 2018	SELL	$64.88 - $75.68 $47,167 - $55,019	-727 Reduced 1.18%	61,029 $4.32 Million
Q1 2018 May 09, 2018	SELL	$72.84 - $88.8 $65,993 - $80,452	-906 Reduced 1.45%	61,756 $4.66 Million
Q4 2017 Jan 16, 2018	SELL	$71.15 - $83.52 $97,831 - $114,840	-1,375 Reduced 2.15%	62,662 $4.49 Million
Q3 2017 Nov 21, 2017	SELL	$72.11 - $85.47 $43,193 - $51,196	-599 Reduced 0.93%	64,037 $5.19 Million
Q2 2017 Aug 14, 2017	BUY	N/A	64,636	64,636 $4.58 Million

Others Institutions Holding GILD

# of Institutions

1,885

Shares Held

Call Options Held

8.71M

Put Options Held

8.02M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.5B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Optimum Investment Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Optimum Investment Advisors with notifications on news.

Account

Optimum Investment Advisors Gilead Sciences, Inc. Transaction History